Currently, three SMA medicines are approved by the European Medicines Agency (EMA). The charts below show the access situation for these medicines by country. In addition to these approved treatments, several others are being evaluated in clinical trials.
SMA is usually diagnosed through a genetic blood test to check for the presence of the SMN1 gene. Access to SMA newborn screening and early treatment are crucial to improve health outcomes in SMA.
Access is greater than access to diagnostics and SMA medicines. It means also access to information regarding the different European healthcare systems.
Keep up-to-date with the OdySMA project. Sign up to receive our digital newsletter
OdySMA is a participatory advocacy tool. Therefore SMA Europe cannot warrant the completeness, reliability, or absolute accuracy of the data shared on OdySMA, as there may be changes that our members and supporters do not immediately inform us of. Should you identify inaccuracies or omissions, please contact laura.gumbert@sma-europe.eu us and let us know. We count on you!